Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas S. Larsen, Krish Patel, Ulrich Jäger, Robert F. Manges, Lorenz Trümper, Hele Everaus, Nagesh Kalakonda, Peter Brown, Judit Meszaros Jørgensen, David Cunningham, Justine Dell’Aringa, Brian Fox, Neus Domper Rubio, Nurgul Kilavuz, Marie Laure Casadebaig, Oliver Manzke, Javier Munoz

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience